D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $30 Price Target

Benzinga · 5d ago
D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $30 price target.